Celyad Oncology S.A.
$0.25▲ 2.04%(+$0.01)
TickerSpark Score
66/100
▌ Solid
68
Valuation
100
Profitability
55
Growth
76
Health
30
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYAD.BR research report →
52-Week Range18% of range
Low
$0.16
Current
$0.25
High
$0.65
Company Overviewwww.celyad.com
About the company
Celyad Oncology S. A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology.
- CEO
- Michel E. J. Lussier
- IPO
- 2013
- Employees
- 17
- HQ
- Mont-Saint-Guibert, BE
Price Chart
-38.56% · this period
Valuation
- Market Cap
- $11.19M
- P/E
- 12.14
- P/S
- 532.88
- P/B
- 4.25
- EV/EBITDA
- -1.35
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 9195.24%
- Op Margin
- -33957.14%
- Net Margin
- 3833.33%
- ROE
- -242.11%
- ROIC
- -287.54%
Growth & Income
- Revenue
- $21.00K · -88.71%
- Net Income
- $830.00K · 114.25%
- EPS
- $0.02 · 113.86%
- Op Income
- $-7,182,000
- FCF YoY
- -21.48%
Performance & Tape
- 52W High
- $0.65
- 52W Low
- $0.16
- 50D MA
- $0.29
- 200D MA
- $0.26
- Beta
- 1.20
- Avg Volume
- 14.72K
Get TickerSpark's AI analysis on CYAD.BR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Coverage · CYAD.BR
Our CYAD.BR coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on CYAD.BR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CYAD.BR report →